Beijing Tong Ren Tang Chinese Medicine Company Limited risk profile
36 Normal where most of the sector sits
Measured 1 September 2026 from TQR's filed statements. Recomputed nightly.
36 (Normal), driven by Market expectation at 71, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 71 | Stretched | Worsening | Drawdown from the 52-week high — 38.2% |
| Operating pressure | 54 | Elevated | Easing | Operating-margin drift — -11.7 percentage points |
| Cash conversion | 10 | Contained | Easing | Capital spending against operating cash — 0.05x |
| Leverage and coverage | 0 | Contained | Stable | Net debt to EBITDA — -3.45x |
| Competitive position | 39 | Normal | Stable | Revenue-growth gap against peers — -42.2 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Beijing Tong Ren Tang Chinese Medicine Company Limited